Physician profile
Mossaab Shuraih
NPI 1144318270
$24,895.52
in general payments reported to CMS, 2019-2025
18 companies · $5,084 in 2025
The $5,084 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,416 · 2020: $1,300 · 2021: $1,494 · 2022: $3,312 · 2023: $2,117 · 2024: $2,172 · 2025: $5,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,055 · Travel and Lodging: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,054.75 |
| Travel and Lodging | $1,318.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,056.74 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Micra, Cobalt Dr Mri Surescan |
| Pfizer INC. | $6,804.30 | 2019-2024 | |
| Boston Scientific Corporation | $3,181.88 | 2019-2024 | Watchman Access System, Rhythmia Mapping System, Lux-Dx Insertable Cardiac Monitor |
| Biosense Webster, INC. | $1,269.38 | 2019-2025 | Carto 3, Soundstar, Lasso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $974.68 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $799.54 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $604.33 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $561.28 | 2019-2023 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $155.77 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $135.43 | 2022-2023 | |
| Atricure, INC. | $101.43 | 2022 | |
| Cvrx, INC. | $90.74 | 2025 | Barostim Neo System |
| Esperion Therapeutics, INC. | $57.99 | 2021 | |
| Abbott Laboratories | $31.28 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $30.20 | 2022-2023 | Farxiga |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $16.50 | 2024 | |
| Elutia, INC. | $13.13 | 2022 | |
| Gilead Sciences, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mossaab Shuraih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.